Ruth Turner

Ruth brings more than 25 years of expertise in Regulatory Affairs recognized for delivering excellence by creating, scaling and leading high-performing teams.

In her role at Ipsen, Ruth leads regulatory affairs and quality in the US where she is responsible for regulatory and quality compliance for all of Ipsen’s U.S. marketed products as well as products under development for the local market.

Prior to joining Ipsen, Ruth held executive and senior leadership roles at Angion, Shire/Takeda, Fresenius Medical Care, and Genzyme, overseeing global regulatory affairs and strategy teams. Most recently, she served as senior vice president of regulatory affairs and pharmacovigilance operations for Candel Therapeutics, driving operational vision, strategy, support and readiness to move pipeline products in late-stage development. Throughout her career, she has been recognized for driving international strategy, moving products from inception to end of life cycle in therapeutic areas across oncology, neurology, renal, primary immunodeficiency disease (PID), cardiovascular, ophthalmology and pulmonary.

Ruth is a graduate of the University of Massachusetts Amherst and holds a Bachelor of Science in microbiology. She is active in numerous professional organizations, including Chief, the Drug Information Association (DIA), the Parenteral Drug Association (PDA), the American Society of Cell & Gene Therapy (ASCGT), and the Regulatory Affairs Professionals Society (RAPS).